Shp2 inhibitor compositions for use in treating cancer
AssigneeRevolution Medicines, Inc.
InventorsRobert J. NICHOLS, Trever G. BIVONA, Dana NEEL
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods of treating diseases or disorders using allosteric inhibitors of SHP2 and to methods and diagnostic tests for identifying subjects likely to respond to such allosteric inhibitors of SHP2. In particular, the present disclosure provides diagnostic and therapeutic uses related to certain Receptor Tyrosine Kinase (RTK) mutations that are indicative of sensitivity to allosteric SHP2 inhibitors.
Claims27
A method for identifying whether a subject has a cancer that is sensitive to SHP2 inhibition, the method comprising determining whether the cancer comprises one or more cells containing an oncogenic tyrosine kinase fusion that causes MAPK activation, and, if so, identifying the subject as having a cancer that is sensitive to SHP2 inhibition.
(canceled)
A method for killing cancer cells with a SHP2 inhibitor, the method comprising the steps of:
- a. determining whether the cancer cells contain an oncogenic tyrosine kinase fusion that causes MAPK activation;
- and
- b. contacting the cancer cells with the SHP2 inhibitor if the cancer cells contain an oncogenic tyrosine kinase fusion that causes MAPK activation.
A method for treating a patient with a SHP2 inhibitor, wherein the patient has cancer, the method comprising the steps of:
- a. determining whether the patient has a SHP2-sensitive cancer by:
- i. obtaining or having obtained a biological sample from the patient;
- and
- ii. performing or having performed an assay on the biological sample to determine if the patient has a tumor comprising one or more cells that contain an oncogenic tyrosine kinase fusion that causes MAPK activation;
- and
- b. administering the SHP2 inhibitor to the patient if the patient has a tumor comprising one or more cells containing an oncogenic tyrosine kinase fusion that causes MAPK activation.
(canceled)
A method for treating a subject having a tumor with a SHP2 inhibitor, the method comprising:
- a. determining whether a biological sample obtained from the subject contains an oncogenic tyrosine kinase fusion protein comprising a N-terminal fusion partner that causes the fusion protein to localize in an endosome;
- and
- b. administering to the subject an inhibitor of SHP2 if the biological sample contains an oncogenic tyrosine kinase fusion protein comprising a N-terminal fusion partner that causes the fusion protein to localize in an endosome.
25-28. (canceled)
Dependencies are inferred from the claim text.